Corporate Profile

Biomolecular Pharma, Inc. is an innovative company developing pharmaceutical agents. The company is on the leading edge of investigations associated with the vast amounts of accumulated data on molecular structures and creative use of information regarding chemical molecules and biological macromolecules. The strategic scientific direction is focused on designing novel candidate pharmacologic agents for a wide range of disorders including primary brain cancers, multiple sclerosis, various viral infections, as well as other neurological diseases.

Charlottetown, Prince Edward Island, Canada has large cooperative research facilities, the University of Prince Edward Island, and the National Research Council of Canada, all of which have aided in making our initial pharmaceutical agents possible.

Biomolecular Pharma has achieved: (1) an agent which will destroy primary brain tumor cells in all phases of the cell cycle. This has been accomplished with two (2) courses of the agent. In three months a three (3) cm. tumor is no longer present. This opens the door of possible destruction of the tumor stem cell which would be a curative situation. (2) We have a carrier drug which will transport small chemical molecules across the Blood Brain Barrier. These small chemical molecules will not cross the Blood Brain Barrier alone. (3) It is an anti-viral agent that prevents the replication of the measles virus and the viruses of Influenza "A" (H1N1) and Influenza "B" (common flu).